Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 14Prostatic Neoplasms 12Multiple Myeloma 8Neoplasm Metastasis 6Osteoporosis 4Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Lung Neoplasms 2Kidney Neoplasms 2Bone Diseases 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Osteonecrosis 1Oligodendroglioma 1Neovascularization, Pathologic 1Neoplasms by Site 1Neoplasms 1Neoplasm, Residual 1Neoplasm Micrometastasis 1Nasopharyngeal Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma 1

Interventions

Zoledronic Acid 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Diseases, Metabolic × Zoledronic Acid × Clear all
NCT00181584 2013-07-11

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Massachusetts General Hospital

Phase 2 Completed
60 enrolled
Genitourinary

Bone Diseases, Metabolic, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡